Conditions: Metastatic Colorectal Cancer
Keywords: colorectal cancer chemotherapy cancer metastatic irinotecan EGFr epidermal growth factor
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 28
Healthy volunteers: no

Brief summary:
The primary objective of this study is to determine if panitumumab affects the pharmacokinetic (PK) profile of irinotecan.

Detailed description:

Arms:
arm 1: Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.

Interventions: intervention 1: Panitumumab intervention 2: Irinotecan
Intervention descriptions: intervention 1: The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter. intervention 2: The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.

Protocol document: